Our Research

Discover our recent findings, catch up with news, and review in-depth resources.

Resolian - USP and USP : What Pharma Manufacturers Need to Know Before May 2026

Blog

USP 665 and USP 1665: What Pharma Manufacturers Need to Know

With mandatory USP 665 and USP 1665 compliance arriving in May 2026, pharma and biopharma manufacturers must act now. Learn how Resolian’s E&L experts can help you build a compliant, risk-based testing programme.
Read more
Resolian | Making Informed Decisions - A Guide to Selecting the Right Contract Research Organization Partner

Blog

Making Informed Decisions: A Guide to Selecting the Right Contract Research Organization Partner

How do you evaluate a CRO beyond price? This guide covers technical capabilities, quality systems, geographical reach, and partnership factors that matter most.
Read more
Ultra-Low B Cell Detection: Flow Cytometry Method Validation to 10 cells/μL | Resolian Case Study

Case Studies

Ultra-Low B Cell Detection: Flow Cytometry Method Validation to 10 cells/μL

Learn how Resolian developed a validated flow cytometry method achieving B cell detection down to 0.5 cells/μL with 5.27% CV using innovative matrix design.
Read more

Case Studies | Videos

Elemental Impurities in Medical Devices: Risk Assessment

Extraction method drastically affects elemental analysis results. Resolian’s comparison shows simulated-use extraction provides realistic risk assessment vs total digestion.
Read more
Chiral SFC Method Development Using DoE | Resolian

Case Studies | Videos

Chiral SFC Method Development Using DoE

Chiral method development is unpredictable and time-consuming. Resolian’s SFC workflow with Design of Experiments reduces workload while improving efficiency
Read more

News

Resolian and GoBroad Healthcare Group Partnership Streamlines China-Global Clinical Trial Access

Resolian signs a nonexclusive strategic partnership agreement with GoBroad Healthcare Group, a China-based, clinically focused innovation technology platform and Academic Research Organization (ARO).
Read more
Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Linkedin

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.